A Study of LY900014 in Participants With Type 1 Diabetes

Status:	Active, not recruiting
Conditions:	Diabetes, Diabetes
Therapuetic Areas:	Endocrinology
Healthy:	No
Age Range:	18 - Any
Updated:	12/6/2018
Start Date:	July 17, 2017
End Date:	September 5, 2019

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D

The main purpose of this study is to evaluate the efficacy of the study drug LY900014
compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in
adults with type 1 diabetes (T1D).

Inclusion Criteria:

- Have T1D for at least 1 year prior to screening and continuously using insulin for at
least 1 year.

- HbA1c of ≥7.0 and ≤9.5%.

- Use insulin lispro, insulin aspart, or insulin glulisine as prandial insulin.

- Use insulin glargine, insulin detemir, insulin degludec, or neutral protamine Hagedorn
(NPH) insulin as basal insulin.

Exclusion Criteria:

- Have used other antihyperglycemic medications or therapies (inhaled, oral or
injectable) within 90-days of screening.

- Have had more than 1 severe hypoglycemic episode within 6 months of screening.

- Have had more than 1 hospitalization related to hyperglycemia or diabetic ketoacidosis
within 6 months of screening.

- Have clinically significant gastrointestinal disease.

We found this trial at

sites

Partners in Nephrology & Endocrinology

Pittsburgh, Pennsylvania 15224

Principal Investigator: Patricia Bononi

Phone: 412-683-4550

from

Pittsburgh, PA